公开(公告)号：US20250154512A1

公开(公告)日：2025-05-15

申请号：US19028462

申请日：2025-01-17

Applicant: AMGEN INC.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20210139912A1

公开(公告)日：2021-05-13

申请号：US16771907

申请日：2018-12-12

Applicant: AMGEN INC.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20160024159A1

公开(公告)日：2016-01-28

申请号：US14773756

申请日：2014-03-12

Applicant: AMGEN INC

Inventor： Justin K. MURRAY ,  Jerry Ryan HOLDER ,  Malgorzata WANSKA ,  Christopher M. TEGLEY ,  James R. FALSEY ,  Elizabeth M. DOHERTY ,  Leslie P. MIRANDA ,  Kaustav BISWAS ,  Bin WU ,  Kelvin SHAM ,  Jason C. LONG

IPC: C07K14/435 ,  A61K38/17 ,  A61K47/48

CPC classification number: C07K14/43518 ,  A61K38/00 ,  A61K38/16 ,  A61K38/1709 ,  A61K38/1767 ,  A61K47/643 ,  A61K47/6817 ,  C07K14/435 ,  C07K14/46 ,  C07K14/47

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周受限制的NaV1.7抑制剂。 在一些公开的实施方案中，分离的多肽是NaV1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。

公开(公告)号：US20160304570A1

公开(公告)日：2016-10-20

申请号：US15134305

申请日：2016-04-20

Applicant: AMGEN INC.

Inventor： Justin K. MURRAY ,  Leslie P. MIRANDA ,  Stefan I. MCDONOUGH

IPC: C07K14/435 ,  C07K16/44 ,  A61K47/48

CPC classification number: C07K14/43518 ,  A61K38/00 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6817 ,  C07K14/00 ,  C07K16/44 ,  C07K2317/35 ,  C07K2317/76 ,  C07K2319/30

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7 and/or NaV1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周受限制的NaV1.7抑制剂。 在一些公开的实施方案中，分离的多肽是NaV1.7和/或NaV1.3的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。

公开(公告)号：US20150023988A1

公开(公告)日：2015-01-22

申请号：US14207445

申请日：2014-03-12

Applicant: AMGEN INC.

Inventor： Justin K. MURRAY ,  Jerry Ryan HOLDER ,  Malgorzata WANSKA ,  Christopher M. TEGLEY ,  James R. FALSEY ,  Elizabeth M. DOHERTY ,  Leslie P. MIRANDA

IPC: A61K47/48 ,  C07K16/00 ,  A61K38/17 ,  C07K14/435

CPC classification number: A61K47/48438 ,  A61K38/00 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6817 ,  C07K14/43518 ,  C07K14/705 ,  C07K16/44

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周限制的Nav1.7抑制剂。 在一些公开的实施方案中，分离的多肽是Nav1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。

公开(公告)号：US20240084301A1

公开(公告)日：2024-03-14

申请号：US18357495

申请日：2023-07-24

Applicant: AMGEN INC.

Inventor： Elizabeth Ann KILLION ,  Jerry Ryan HOLDER ,  Bryan MEADE ,  Justin K. MURRAY ,  Oliver R. HOMANN ,  Briana Renee GRIEGO ,  Murielle Marie VENIANT ELLISON

IPC: C12N15/113 ,  A61P1/16 ,  A61P3/04

CPC classification number: C12N15/113 ,  A61P1/16 ,  A61P3/04 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322

Abstract: The present application relates to compositions and methods for modulating expression of Family with Sequence Similarity 13 Member A (FAM13A) protein. In particular, the present application relates to nucleic acid-based therapeutics for reducing FAM13A gene expression via RNA interference and methods of using such nucleic acid-based therapeutics to reduce abdominal adiposity, reduce body weight, reduce fat mass, improve metabolic parameters including insulin resistance and non-alcoholic steatohepatitis (NASH), and reduce risk of myocardial infarction.

公开(公告)号：US20230279399A1

公开(公告)日：2023-09-07

申请号：US18007560

申请日：2021-06-03

Applicant: Amgen Inc.

Inventor： Daniel C. H. LIN ,  Michael OLLMANN ,  Justin K. MURRAY ,  Bradley J. HERBERICH ,  Amrita DAS ,  Patrick COLLINS ,  Oliver HOMANN

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/315 ,  C12N2310/11

Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20220307022A1

公开(公告)日：2022-09-29

申请号：US17615520

申请日：2020-06-01

Applicant: AMGEN INC.

Inventor： Amrita DAS ,  Bradley J. HERBERICH ,  Justin K. MURRAY ,  Oliver HOMANN ,  Michael OLLMANN ,  Daniel C.H. LIN

IPC: C12N15/113 ,  A61K31/713 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20220017906A1

公开(公告)日：2022-01-20

申请号：US17312721

申请日：2019-12-10

Applicant: Amgen Inc.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20210108212A1

公开(公告)日：2021-04-15

申请号：US17080771

申请日：2020-10-26

Applicant: AMGEN INC.

Inventor： Michael OLLMANN ,  Yang LI ,  Jun ZHANG ,  Kaustav BISWAS ,  Oliver HOMANN ,  Leslie P. MIRANDA ,  Justin K. MURRAY ,  Bin WU ,  Oh Kyu YOON ,  John Gordon ALLEN ,  Chawita NETIROJJANAKUL ,  Yuan CHENG

IPC: C12N15/113 ,  A61P9/10 ,  A61P3/06 ,  C07K16/28

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.